Xinyuan Cao

Xinyuan Cao

Auto-generated profile, based on publicly available information

Xinyuan Cao

Ningxia Medical University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2026 in Virulence
Verified
Journal Article
Open access
XCXinyuan Cao
Xinyuan Cao
XYXiaorong Yang
Xiaorong Yang
LDLixia Dai
Lixia Dai
XLXueyan Liu
Xueyan Liu
ZGZile Gong
Zile Gong
CBChangcai Bai
Changcai Bai
The clinical persistence of methicillin-resistant Staphylococcus aureus (MRSA) reflects a synergistic interplay between antimicrobial resistance and virulence programs that promote immune evasion, ...

20 July 2026 in Advanced Science
Verified
Journal Article
Open access
XYXiaorong Yang
Xiaorong Yang
XCXinyuan Cao
Xinyuan Cao
LDLixia Dai
Lixia Dai
FYFeng Yang
Feng Yang
JWJing Wang
Jing Wang
XSXiaofei Shang
Xiaofei Shang
The persistent threat of methicillin‐resistant Staphylococcus aureus (MRSA) underscores the critical need for antimicrobials with novel mechanisms of action. Herein, we describe the discovery of Py‐27, a pyrazole‐derived compound exhibiting potent bactericidal activity against MRSA. A chemoproteomic approach identified aspartate transcarbamoylase (ATCase), a key enzyme in de novo pyrimidine synthesis, as the specific target of Py‐27. Biophysical and enzymatic assays confirmed its high‐affinity binding and inhibition of ATCase, while genetic knockout established ATCase as a druggable metabolic vulnerability in MRSA. Mechanistically, Py‐27 disrupts pyrimidine synthesis, thereby impairing DNA replication, perturbing metabolic homeostasis, and ultimately inducing lethal oxidative damage. Notably, Py‐27 eradicates mature biofilms while exhibiting a low resistance propensity and favorable toxicological profiles. In animal infection models, Py‐27 demonstrated superior in vivo efficacy compared to vancomycin and promoted infection resolution and tissue repair. This study demonstrates the potential of pyrazole‐amide compounds targeting ATCase for the treatment of MRSA infections.